ResApp Health Limited has received strong commitments from existing and new institutional and sophisticated investors to raise A$12.5m ($9.73m).
To raise the capital, the company has placed 62.5m shares of its common stock at a price of A$0.20 ($0.15) each. The joint lead managers for the offering include Jett Capital Advisors, Empire Capital Partners and CPS Capital Group.
The funds will be used to expedite the US FDA approval for the company’s adult diagnostic test, to expand the company’s presence in the US, Europe and Asia, and to develop more devices for chronic respiratory disease management.
Immunexpress, a molecular diagnostics company based in Seattle, US, has collaborated with the Academic Medical Center (AMC), a research institution at the University of Amsterdam, to develop sepsis-related biomarker panels.
The two partners will clinically evaluate sepsis and sepsis-related biomarker signatures of the host response, pursuant to the agreement.
The four-year long collaboration will help advance the commercialisation of the diagnostic company’s pipeline of host response products targeted at improving sepsis patient management.
While Immunexpress provides monetary support to the project along with bio-informatic partnering, lead product development and commercialisation, AMC will publish the findings.
AMC will also continue its research and development as per the directions of Immunexpress and risk stratifications of sepsis (MARS) consortium, which involves a clinical trial of more than 7,500 ICU patients with sepsis or those susceptible to it.
Viveve Medical, a women’s health company, has announced that it will raise up to $10m in an initial public offering (IPO). It has completed filing with the US Securities and Exchange Commission (SEC) in this respect.
It also provides underwriters a 45-day option to buy its common stock amounting to 15% of the public shares, to cover any over-allotments. If the option is exercised, the company will receive gross proceeds of $11.5m.
The IPO proceeds will be used for the commercialisation of the company’s products, to expand global regulatory clearances, to research and develop new treatment tips, and for general corporate and working capital purposes.
Everly Well, a digital health start-up based in Texas, US, has raised $2.5m in seed funding to expand its range of regulatory-compliant, at-home diagnostic tests.
Predicine and CloudHealth Genomics have agreed to jointly promote the former’s next-generation sequencing (NGS)-based liquid biopsy diagnostic tests in the China oncology market.
In mid-2016, Predicine will introduce PrediSeq, its cell-free DNA (cfDNA) NGS diagnostic tests for the oncology sector. It also plans to launch a portfolio of additional tests for other cancer indications in 2017.
CloudHealth will provide clinical genetic testing infrastructure and high-throughput sequencing capacity as part of the agreement.
Predicine is a company specialising in precision diagnostics, whereas CloudHealth develops genome sequencing testing products.
Image: A large building. Photo:courtesy of Janericloebe